About
MacuCLEAR Inc.™ is a specialty development-stage pharmaceutical company focused on developing and commercializing novel solutions for vascular disorders of the eye.
MC-1101, MacuCLEAR’s lead compound, is a patent-pending topically delivered drug for treating and stopping the progression of dry Age-related Macular Degeneration (AMD). Subsequent targets for dry AMD are diabetic retinopathy and ischemic retinopathy. In April 2007, MacuCLEAR completed a private placement of funds to complete preclinical studies and to advance the product to an Investigational New Drug (IND).